Neurogene Inc. is a clinical-stage biotechnology company. Co., through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is under development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. We show 22 historical shares outstanding datapoints in our coverage of NLTX's shares outstanding history.
Understanding the changing numbers of NLTX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like NLTX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching NLTX by allowing them to research NLTX shares outstanding history
as well as any other stock in our coverage universe. |
Free NLTX Email Alerts:
Video: Shares Outstanding Importance
